The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 14, 2025

Filed:

Aug. 30, 2019
Applicant:

Yale University, New Haven, CT (US);

Inventors:

Elias Quijano, Durham, CT (US);

Audrey Turchick, Chelmsford, MA (US);

Peter Glazer, Guilford, CT (US);

Assignee:

YALE UNIVERSITY, New Haven, CT (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/44 (2006.01); A61K 31/7088 (2006.01); A61K 35/14 (2015.01); A61K 39/00 (2006.01); A61K 47/69 (2017.01); A61K 48/00 (2006.01); A61P 43/00 (2006.01); C07K 16/40 (2006.01); C12N 15/10 (2006.01); C12N 15/11 (2006.01);
U.S. Cl.
CPC ...
C07K 16/44 (2013.01); A61K 31/7088 (2013.01); A61K 35/14 (2013.01); A61K 47/6937 (2017.08); A61K 48/0008 (2013.01); A61P 43/00 (2018.01); C12N 15/102 (2013.01); C12N 15/11 (2013.01); A61K 2039/505 (2013.01); C07K 16/40 (2013.01); C07K 2317/622 (2013.01); C07K 2317/626 (2013.01); C07K 2317/77 (2013.01);
Abstract

Compositions for enhanced gene editing and methods of use thereof are. The composition contains a cell-penetrating antibody and a donor oligonucleotide containing a sequence that can correct a mutation in a cell's genome. Preferably, the composition does not contain a nuclease, PNA, or nanoparticle. The compositions are used to modify the genome of a cell by contacting the cell with an effective amount of the composition. Genomic modification occurs at a higher frequency both ex vivo and in vivo, when cells are contacted with the cell-penetrating antibody and donor oligonucleotide as compared to the absence of the cell-penetrating antibody.


Find Patent Forward Citations

Loading…